Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection
- PMID: 16495547
- PMCID: PMC1418682
- DOI: 10.1128/IAI.74.3.1745-1750.2006
Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection
Abstract
We previously reported the cloning and characterization of leptospiral immunoglobulin-like proteins LigA and LigB of Leptospira interrogans. LigA and LigB are conserved at the amino-terminal region but are variable at the carboxyl-terminal region. Here, we evaluate the potential of recombinant LigA (rLigA) as a vaccine candidate against infection by L. interrogans serovar Pomona in a hamster model. rLigA was truncated into conserved (rLigAcon) and variable (rLigAvar) regions and expressed in Escherichia coli as a fusion protein with glutathione-S-transferase (rLigA). Golden Syrian hamsters were immunized at 3 and 6 weeks of age with rLigA (rLigAcon and rLigAvar) with aluminum hydroxide as an adjuvant. Hamsters given recombinant glutathione-S-transferase (rGST)-adjuvant and phosphate-buffered saline-adjuvant served as nonvaccinated controls. Three weeks after the last vaccination, all animals were challenged intraperitoneally with 10(8) L. interrogans serovar Pomona bacteria (NVSL 1427-35-093002). All hamsters immunized with recombinant LigA survived after challenge and had no significant histopathological changes. In contrast, nonimmunized and rGST-immunized hamsters were subjected to lethal doses, and the hamsters that survived showed severe tubulointerstitial nephritis. All vaccinated animals showed a rise in antibody titers against rLigA. Results from this study indicate that rLigA is a potential vaccine candidate against L. interrogans serovar Pomona infection.
Figures
Similar articles
-
Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters.Vaccine. 2008 Jan 10;26(2):277-87. doi: 10.1016/j.vaccine.2007.10.029. Epub 2007 Nov 5. Vaccine. 2008. PMID: 18055070
-
Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity.Vaccine. 2009 Jan 14;27(3):378-87. doi: 10.1016/j.vaccine.2008.10.089. Epub 2008 Nov 18. Vaccine. 2009. PMID: 19022317
-
Leptosome-entrapped leptospiral antigens conferred significant higher levels of protection than those entrapped with PC-liposomes in a hamster model.Vaccine. 2009 Nov 5;27(47):6537-45. doi: 10.1016/j.vaccine.2009.08.051. Epub 2009 Sep 1. Vaccine. 2009. PMID: 19729088
-
Leptospirosis in farmed deer in New Zealand : a review.N Z Vet J. 2007 Jun;55(3):102-8. doi: 10.1080/00480169.2007.36750. N Z Vet J. 2007. PMID: 17534410 Review.
-
Expansion of the in vitro assay for Leptospira potency testing to other serovars: case study with Leptospira Hardjo.Biologicals. 2013 Sep;41(5):323-4. doi: 10.1016/j.biologicals.2013.06.003. Epub 2013 Jul 6. Biologicals. 2013. PMID: 23838569 Review.
Cited by
-
Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens. 2023 May 31;12(6):787. doi: 10.3390/pathogens12060787. Pathogens. 2023. PMID: 37375478 Free PMC article. Review.
-
Leptospiral imelysin (LIC_10713) is secretory, immunogenic and binds to laminin, fibronectin, and collagen IV.Appl Microbiol Biotechnol. 2023 Jul;107(13):4275-4289. doi: 10.1007/s00253-023-12573-6. Epub 2023 May 25. Appl Microbiol Biotechnol. 2023. PMID: 37227474
-
LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis.Front Immunol. 2022 Oct 10;13:985802. doi: 10.3389/fimmu.2022.985802. eCollection 2022. Front Immunol. 2022. PMID: 36300125 Free PMC article.
-
Insight into the Structure, Functions, and Dynamics of the Leptospira Outer Membrane Proteins with the Pathogenicity.Membranes (Basel). 2022 Mar 7;12(3):300. doi: 10.3390/membranes12030300. Membranes (Basel). 2022. PMID: 35323775 Free PMC article. Review.
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
References
-
- Andre-Fontaine, G., C. Branger, A. W. Gray, and H. L. Klaasen. 2003. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet. Rec. 153:165-169. - PubMed
-
- Bharti, A. R., J. E. Nally, J. N. Ricaldi, M. A. Matthias, M. M. Diaz, M. A. Lovett, P. N. Levett, R. H. Gilman, M. R. Willig, E. Gotuzzo, and J. M. Vinetz. 2003. Leptospirosis: a zoonotic disease of global importance. Lancet Infect. Dis. 3:757-771. - PubMed
-
- Bolin, C. A., and D. P. Alt. 2001. Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar Hardjo. Am. J. Vet. Res. 62:995-1000. - PubMed
-
- Borer, A., I. Metz, J. Gilad, K. Riesenberg, N. Weksler, G. Weber, M. Alkan, and J. Horowitz. 1999. Massive pulmonary haemorrhage caused by leptospirosis successfully treated with nitric oxide inhalation and haemofiltration. J. Infect. 38:42-45. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
